Cargando…
IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt
Background: Psoriatic arthritis (PsA) is a chronic inflammatory joint disease within the spondyloarthritis spectrum. IL-12p40/IL-23p40 blockade reduces PsA disease activity, but its impact on synovial inflammation remains unclear. Objectives: To investigate the cellular and molecular pathways affect...
Autores principales: | Fiechter, Renée H., de Jong, Henriëtte M., van Mens, Leonieke J. J., Fluri, Inka A., Tas, Sander W., Baeten, Dominique L. P., Yeremenko, Nataliya G., van de Sande, Marleen G. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7971179/ https://www.ncbi.nlm.nih.gov/pubmed/33746955 http://dx.doi.org/10.3389/fimmu.2021.611656 |
Ejemplares similares
-
Anti-IL-17A treatment reduces serum inflammatory, angiogenic and tissue remodeling biomarkers accompanied by less synovial high endothelial venules in peripheral spondyloarthritis
por: Kaaij, Merlijn H., et al.
Publicado: (2020) -
IL-17 in spondyloarthritis: is the T-party over?
por: Yeremenko, Nataliya, et al.
Publicado: (2011) -
Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment
por: Zhou, Jiong, et al.
Publicado: (2020) -
Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice
por: van Mens, Leonieke J. J., et al.
Publicado: (2017) -
IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
por: Noordenbos, Troy, et al.
Publicado: (2011)